Exicure to Present Poster at SID 2019 Annual Meeting Demonstrating Bi-Specific Gene Targeting in Dermatology

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/DigitalDrugDesign?src=hash" target="_blank"gt;#DigitalDrugDesignlt;/agt;–Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced a poster presentation at the Society for
Investigative Dermatology (SID) Meeting, May 8-11, in Chicago. The
poster, titled, “Topically-applied bispecific nanoconstructs
concurrently targeting TNFA and IL17RA reverse psoriasis-like changes in
the imiquimod-induced psoriasis mouse model,” will be presented by
Haoming Liu of the Northwestern Skin Disease Research Center at
Northwestern University, which is directed by Exicure Advisory Board
Member Amy Paller, M.D.

Session Date/Time: Saturday, May 11, 12:45 – 2:45 p.m. CT

Poster session: 3

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing
therapeutics for immuno-oncology, inflammatory diseases and genetic
disorders based on our proprietary Spherical Nucleic Acid, or SNA
technology. We believe Exicure’s proprietary SNA™ architecture has
distinct chemical and biological properties that may provide advantages
over other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure’s lead program is in a Phase1b/2 trial in patients
with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com

Contacts

MacDougall
Karen Sharma
781-235-3060
[email protected]